The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.
 
Zishuo Ian Hu
No Relationships to Disclose
 
Anna M. Varghese
Consulting or Advisory Role - Cancer Genetics (I); Sequenom (I)
Research Funding - BioMed Valley Discoveries (Inst); Lilly (Inst); Verastem (Inst)
 
Jinru Shia
No Relationships to Disclose
 
Alice Zervoudakis
No Relationships to Disclose
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Celgene
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; Merck Serono; Merrimack
 
Sree Bhavani Chalasani
No Relationships to Disclose
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; McKesson
Research Funding - AbbVie (Inst); AstraZeneca (Inst); Biomarin (Inst); Medivation (Inst); Myriad Genetics (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Allergan (I); Genentech/Roche (I); Optos (I); Regeneron (I)
 
Philip Caron
No Relationships to Disclose
 
David Paul Kelsen
No Relationships to Disclose
 
David Klimstra
No Relationships to Disclose
 
Daniel W. Kelly
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)